Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adendra Launched To Unlock Immunotherapy Potential Of Dendritic Cells

Another Spin-Out From London’s Crick Institute

Executive Summary

Expertise in dendritic cells could help generate new targets in cancer and autoimmune disease immunotherapy.

You may also be interested in...



Cash Injection Puts Quell At Forefront Of Treg Therapy

The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.

Takeda Buys Out Partner GammaDelta In Cell Therapy Push

Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.

Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel